NCT03396107 is a Phase 3 clinical trial of Dexamethasone in Cesarean Section Complications, sponsored by Assiut University.

Who is sponsoring NCT03396107?

NCT03396107 is sponsored by Assiut University.

What drugs are being tested in NCT03396107?

Interventions in NCT03396107: Dexamethasone, Placebo.

What condition does NCT03396107 study?

NCT03396107 studies Cesarean Section Complications.

Is NCT03396107 still recruiting?

NCT03396107 is currently completed. Last updated 21 June 2021.

Last reviewed 2021-06-21 · How we verify

NCT03396107

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antenatal Corticosteroid in Elective Cesarean Section

Completed Phase 3 Last updated 21 June 2021

What this trial tests

Phase 3 trial testing Dexamethasone in Cesarean Section Complications in 498 participants. Completed in 24 May 2020.

Timeline

17 May 2018

Primary endpoint
25 November 2019

24 May 2020

Quick facts

Lead sponsor	Assiut University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	498
Start date	17 May 2018
Primary completion	25 November 2019
Estimated completion	24 May 2020
Sites	1 location across Egypt

Drugs / interventions tested

Dexamethasone (dexamethasone) — full drug profile →
Placebo

Conditions studied

Cesarean Section Complications — all drugs for Cesarean Section Complications →

Sponsor

Assiut University

Who can join

Adults 18 to 35, female only, with Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Caesarean section is a risk factor for the development of neonatal respiratory complications, mostly respiratory distress syndrome (RDS) and transient tachypnoea of the new-born, both in term and preterm infants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexamethasone

Trials testing the same drug.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Cesarean Section Complications

Currently open trials in the same condition.

NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
NCT05224726 — Platelet Rich Plasma for Uterine Scar · NA · recruiting
NCT07130747 — Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section · NA · recruiting
NCT05791630 — The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) · NA · recruiting
NCT07049705 — Factors Influencing Bradycardia During Spinal Anesthesia in Obstetric Patients Undergoing Cesarean Section · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03396107 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 21 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03396107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing